CL2021002104A1 - Compuestos, composiciones y métodos. - Google Patents

Compuestos, composiciones y métodos.

Info

Publication number
CL2021002104A1
CL2021002104A1 CL2021002104A CL2021002104A CL2021002104A1 CL 2021002104 A1 CL2021002104 A1 CL 2021002104A1 CL 2021002104 A CL2021002104 A CL 2021002104A CL 2021002104 A CL2021002104 A CL 2021002104A CL 2021002104 A1 CL2021002104 A1 CL 2021002104A1
Authority
CL
Chile
Prior art keywords
methods
compositions
compounds
stereoisomer
stereoisomers
Prior art date
Application number
CL2021002104A
Other languages
English (en)
Inventor
Maksim Osipov
Vicente Fidalgo Javier De
Robert A Ii Craig
Anthony A Estrada
Jianwen A Feng
Brian M Fox
Arun Thottumkara
Original Assignee
Denali Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Denali Therapeutics Inc filed Critical Denali Therapeutics Inc
Publication of CL2021002104A1 publication Critical patent/CL2021002104A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
    • C07D271/113—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

La presente descripción hace referencia en términos generales a moduladores del factor de iniciación eucariota 2B o una sal farmacéuticamente aceptable, un estereoisómero, una mezcla de estereoisómeros o un profármaco de estos y a métodos para realizarlos y utilizarlos.
CL2021002104A 2019-02-13 2021-08-10 Compuestos, composiciones y métodos. CL2021002104A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962805263P 2019-02-13 2019-02-13
US201962877232P 2019-07-22 2019-07-22

Publications (1)

Publication Number Publication Date
CL2021002104A1 true CL2021002104A1 (es) 2022-04-08

Family

ID=72043948

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2021002104A CL2021002104A1 (es) 2019-02-13 2021-08-10 Compuestos, composiciones y métodos.

Country Status (18)

Country Link
US (2) US11306077B2 (es)
EP (1) EP3923935A4 (es)
JP (1) JP2022520236A (es)
KR (1) KR20210126036A (es)
CN (1) CN113518618A (es)
AU (1) AU2020223228A1 (es)
BR (1) BR112021015639A2 (es)
CA (1) CA3129609A1 (es)
CL (1) CL2021002104A1 (es)
CO (1) CO2021010490A2 (es)
CR (1) CR20210426A (es)
IL (1) IL285302A (es)
MA (1) MA54953A (es)
MX (1) MX2021009669A (es)
PE (1) PE20212023A1 (es)
SG (1) SG11202108552QA (es)
TW (1) TW202045164A (es)
WO (1) WO2020168011A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202000532SA (en) 2017-08-09 2020-02-27 Denali Therapeutics Inc Compounds, compositions and methods
EP3723762A4 (en) 2017-12-13 2021-12-08 Praxis Biotech LLC STRESS INTEGRATED RESPONSE PATH INHIBITORS
CA3100715A1 (en) 2018-06-05 2019-12-12 Praxis Biotech LLC Inhibitors of integrated stress response pathway
PE20212023A1 (es) 2019-02-13 2021-10-18 Denali Therapeutics Inc Compuestos, composiciones y metodos
CN114466654A (zh) 2019-06-12 2022-05-10 普拉西斯生物技术有限责任公司 整合应激反应通路调节剂
AU2021236284A1 (en) 2020-03-11 2022-08-18 Evotec International Gmbh Modulators of the integrated stress response pathway
JP2023546224A (ja) 2020-10-22 2023-11-01 エヴォテック・インターナショナル・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 統合ストレス応答経路のモジュレーター
US20230391763A1 (en) 2020-10-22 2023-12-07 Evotec International Gmbh Modulators of the integrated stress response pathway
MX2023004623A (es) 2020-10-22 2023-05-12 Evotec Int Gmbh Moduladores de la via integrada de respuesta al estres.
CN116710427A (zh) * 2020-12-18 2023-09-05 戴纳立制药公司 化合物的固体形式
WO2024032501A1 (zh) * 2022-08-08 2024-02-15 深圳众格生物科技有限公司 一种化合物、包含其的药物组合物及其用途

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6429207B1 (en) 1997-11-21 2002-08-06 Nps Pharmaceuticals, Inc. Metabotropic glutamate receptor antagonists and their use for treating central nervous system diseases
CA2315050C (en) 1998-10-16 2009-02-03 Suntory Limited Aminophenoxyacetic acid derivatives and pharmaceutical composition containing thereof
AR024077A1 (es) 1999-05-25 2002-09-04 Smithkline Beecham Corp Compuestos antibacterianos
WO2001081317A1 (en) * 2000-04-26 2001-11-01 Gliatech, Inc. Chiral imidazoyl intermediates for the synthesis of 2-(4-imidazoyl)-cyclopropyl derivatives
WO2002080928A1 (en) * 2001-04-03 2002-10-17 Merck & Co., Inc. N-substituted nonaryl-heterocyclo amidyl nmda/nr2b antagonists
JO2397B1 (en) 2002-12-20 2007-06-17 ميرك شارب اند دوم كوربوريشن Terazol derivatives as beta-hydroxy steroid dihydrogenase-1 inhibitors
NZ589252A (en) 2004-09-02 2012-06-29 Vertex Pharma Quinazolines useful as inhibitors of voltage-gated sodium channels
CA2608072A1 (en) 2005-05-24 2006-11-30 Astrazeneca Ab Aminopiperidine quinolines and their azaisosteric analogues with antibacterial activity
ES2443242T3 (es) * 2005-12-23 2014-02-18 Zealand Pharma A/S Compuestos modificados miméticos de lisina
AU2007309117A1 (en) 2006-10-20 2008-05-02 Arete Therapeutics, Inc. Phenylurea compounds as soluble epoxide hydrolase inhibitors
JP5274553B2 (ja) 2007-06-15 2013-08-28 アクテリオン ファーマシューティカルズ リミテッド ３−アミノ−６−（１−アミノ−エチル）−テトラヒドロピラン誘導体
MA32956B1 (fr) 2008-12-12 2012-01-02 Actelion Pharmaceuticals Ltd Derives de 5-amino-2-(1-hydroxyethyl)-tetrahydropyrane
CA2763589A1 (en) 2009-05-28 2010-12-02 President And Fellows Of Harvard College N,n'-diarylurea compounds and n,n'-diarylthiourea compounds as inhibitors of translation initiation
SG176722A1 (en) 2009-06-17 2012-01-30 Vertex Pharma Inhibitors of influenza viruses replication
TWI538905B (zh) 2010-12-22 2016-06-21 Ｈ 朗德貝克公司 雙環［３．２．１］辛基醯胺衍生物及其用途
BR112013021537B1 (pt) 2011-02-24 2021-08-10 Nerviano Medical Sciences S.R.L. Derivados de tiazolilpenil-benzenosulfonamido como inibidores da quinase
PL2684880T3 (pl) 2011-03-10 2018-07-31 Daiichi Sankyo Company, Limited Pochodna dispiropirolidyny
TWI681952B (zh) 2011-04-22 2020-01-11 美商標誌製藥公司 經取代之二胺基甲醯胺及二胺基甲腈嘧啶、其組合物、及以該等治療之方法
US9408392B2 (en) * 2012-02-14 2016-08-09 Syngenta Participations Ag Compounds
EP2905279A4 (en) 2012-10-02 2016-04-20 Sumitomo Dainippon Pharma Co Ltd imidazole
CA2903431C (en) 2013-03-14 2022-12-06 Kalyra Pharmaceuticals, Inc. Bicyclopentane analgesic compounds
US8952171B2 (en) 2013-03-15 2015-02-10 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
CA2904794C (en) 2013-03-15 2021-11-23 Peter Walter Modulators of the eif2alpha pathway
US20160318856A1 (en) 2013-09-11 2016-11-03 The Brigham And Women's Hospital, Inc. Substituted Urea eIF2alpha Kinase Activators
AU2015240535A1 (en) 2014-04-04 2016-10-20 Syros Pharmaceuticals, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
CN106999451B (zh) 2014-09-17 2021-04-02 里科瑞尔姆Ip控股有限责任公司 双环化合物
EP3221306B1 (en) 2014-11-20 2019-11-13 Merck Patent GmbH Heteroaryl compounds as irak inhibitors and uses thereof
EP3233087B1 (en) 2014-12-16 2019-10-02 Axovant Sciences GmbH Geminal substituted quinuclidine amide compounds as agonists of alpha-7 nicotinic acetylcholine receptors
SG11201706820RA (en) 2015-02-25 2017-09-28 Univ Rice William M Desacetoxytubulysin h and analogs thereof
GB201506894D0 (en) * 2015-04-23 2015-06-10 Galapagos Nv Novel dihydropyridoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders
BR112017023764A2 (pt) 2015-05-05 2018-07-31 Bayer Pharma AG derivados de ciclohexano substituído por amido
TW201718557A (zh) 2015-10-08 2017-06-01 歌林達有限公司 經吡唑基取代之四氫吡喃基碸
TW201808914A (zh) * 2016-05-05 2018-03-16 嘉來克生命科學有限責任公司 整合應激途徑之調節劑
TWI763668B (zh) * 2016-05-05 2022-05-11 美商嘉來克生命科學有限責任公司 整合應激途徑之調節劑
TW201808888A (zh) 2016-05-05 2018-03-16 嘉來克生命科學有限責任公司 整合應激途徑之調節劑
TW201808903A (zh) * 2016-05-05 2018-03-16 嘉來克生命科學有限責任公司 整合應激途徑之調節劑
BR112018075598A2 (pt) 2016-06-08 2019-03-26 Glaxosmithkline Intellectual Property Development Limited compostos químicos
CN109563034A (zh) * 2016-06-08 2019-04-02 葛兰素史密斯克莱知识产权发展有限公司 化学化合物
KR102444538B1 (ko) 2016-07-06 2022-09-16 애퀴스트 엘엘씨 요산 수치를 감소시키기 위한 화합물 및 이의 사용
JOP20190072A1 (ar) 2016-10-13 2019-04-07 Glaxosmithkline Ip Dev Ltd مشتقات 1، 3 سيكلوبوتان ثنائي الاستبدال أو آزيتيدين كمثبطات للإنزيم المخلق للبروستاجلاندين d المكون للدم
EP3551610B1 (en) 2016-12-08 2021-08-11 Board of Regents, The University of Texas System Bicyclo[1.1.1]pentane inhibitors of dual leucine zipper (dlk) kinase for the treatment of disease
WO2018225093A1 (en) 2017-06-07 2018-12-13 Glaxosmithkline Intellectual Property Development Limited Chemical compounds as atf4 pathway inhibitors
JP2020525513A (ja) * 2017-07-03 2020-08-27 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ 癌および他の疾患を治療するためのａｔｆ４阻害剤としてのｎ−（３−（２−（４−クロロフェノキシ）アセトアミドビシクロ［１．１．１］ペンタン−１−イル）−２−シクロブタン−１−カルボキサミド誘導体および関連化合物
JP2020525512A (ja) 2017-07-03 2020-08-27 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ 癌および他の疾患を処置するためのＡＴＦ４阻害剤としての２−（４−クロロフェノキシ）−Ｎ−（（１−（２−（４−クロロフェノキシ）エチンアゼチジン（ｅｔｈｙｎａｚｅｔｉｄｉｎ）−３−イル）メチル）アセトアミド誘導体および関連化合物
SG11202000532SA (en) 2017-08-09 2020-02-27 Denali Therapeutics Inc Compounds, compositions and methods
ES2952994T3 (es) 2017-09-01 2023-11-07 Denali Therapeutics Inc Compuestos, composiciones y métodos
WO2019054430A1 (ja) 2017-09-14 2019-03-21 第一三共株式会社 芳香族複素環を有するアミド化合物
JP7324196B2 (ja) 2017-11-02 2023-08-09 カリコ ライフ サイエンシーズ エルエルシー 統合的ストレス経路の調節剤
UY37958A (es) 2017-11-02 2019-05-31 Abbvie Inc Moduladores de la vía de estrés integrada
US20200361881A1 (en) 2017-11-02 2020-11-19 Calico Life Sciences Llc Modulators of the integrated stress pathway
EP3704125A1 (en) 2017-11-02 2020-09-09 Calico Life Sciences LLC Modulators of the integrated stress pathway
UY37956A (es) 2017-11-02 2019-05-31 Abbvie Inc Moduladores de la vía de estrés integrada
CN112204006B (zh) 2017-11-02 2023-11-28 卡里科生命科学有限责任公司 整合应激通路的调节剂
KR20200096523A (ko) 2017-11-02 2020-08-12 칼리코 라이프 사이언시스 엘엘씨 통합된 스트레스 경로의 조절제
UY37957A (es) 2017-11-02 2019-05-31 Abbvie Inc Moduladores de la vía de estrés integrada
MX2020004557A (es) 2017-11-02 2020-10-05 Calico Life Sciences Llc Moduladores de la vía de estrés integrada.
EP3723762A4 (en) 2017-12-13 2021-12-08 Praxis Biotech LLC STRESS INTEGRATED RESPONSE PATH INHIBITORS
US20210130308A1 (en) 2018-03-23 2021-05-06 Denali Therapeutics Inc. Modulators of eukaryotic initiation factor 2
WO2019193541A1 (en) 2018-04-06 2019-10-10 Glaxosmithkline Intellectual Property Development Limited Bicyclic aromatic ring derivatives of formula (i) as atf4 inhibitors
WO2019193540A1 (en) 2018-04-06 2019-10-10 Glaxosmithkline Intellectual Property Development Limited Heteroaryl derivatives of formula (i) as atf4 inhibitors
CN112424167A (zh) 2018-07-09 2021-02-26 葛兰素史密斯克莱知识产权发展有限公司 化学化合物
WO2020031107A1 (en) 2018-08-08 2020-02-13 Glaxosmithkline Intellectual Property Development Limited Chemical compounds
TWI771621B (zh) 2018-10-11 2022-07-21 美商嘉來克生命科學有限責任公司 整合應激路徑之前藥調節劑
EP3924341A4 (en) 2019-02-13 2022-11-02 Denali Therapeutics Inc. COMPOUNDS, COMPOSITIONS AND METHODS
PE20212023A1 (es) 2019-02-13 2021-10-18 Denali Therapeutics Inc Compuestos, composiciones y metodos
US20220177456A1 (en) 2019-03-06 2022-06-09 Denali Therapeutics Inc. Compounds, compositions and methods
JP2022533023A (ja) 2019-04-30 2022-07-21 カリコ ライフ サイエンシーズ エルエルシー 統合的ストレス経路の調節剤としての置換シクロアルキル
WO2020223536A1 (en) 2019-04-30 2020-11-05 Calico Life Sciences Llc Substituted cyclolakyls as modulators of the integrated stress pathway
CN116710427A (zh) 2020-12-18 2023-09-05 戴纳立制药公司 化合物的固体形式

Also Published As

Publication number Publication date
CA3129609A1 (en) 2020-08-20
MA54953A (fr) 2021-12-22
JP2022520236A (ja) 2022-03-29
KR20210126036A (ko) 2021-10-19
CO2021010490A2 (es) 2021-08-30
WO2020168011A1 (en) 2020-08-20
CN113518618A (zh) 2021-10-19
US11958840B2 (en) 2024-04-16
SG11202108552QA (en) 2021-09-29
EP3923935A1 (en) 2021-12-22
US20210292311A1 (en) 2021-09-23
IL285302A (en) 2021-09-30
BR112021015639A2 (pt) 2021-10-05
MX2021009669A (es) 2021-10-13
PE20212023A1 (es) 2021-10-18
AU2020223228A1 (en) 2021-08-26
EP3923935A4 (en) 2022-10-26
TW202045164A (zh) 2020-12-16
US11306077B2 (en) 2022-04-19
CR20210426A (es) 2021-09-30
US20230114472A1 (en) 2023-04-13

Similar Documents

Publication Publication Date Title
CL2021002104A1 (es) Compuestos, composiciones y métodos.
CO2020001220A2 (es) Compuestos, composiciones y métodos
EP4248965A3 (en) Compounds, compositions and methods
DOP2019000201A (es) Compuestos inhibidores del vih
CO2019011809A2 (es) Compuestos de imidazo-piperidina fusionada como inhibidores de jak
JOP20180113A1 (ar) مركبات ,تركيبات وطرق
CO2019015090A2 (es) Métodos de tratamiento para la fibrosis cística
AR109561A1 (es) Compuestos modulares de receptores tipo toll
DOP2020000102A (es) Compuestos útiles para inhibir a cdk7
CL2017001017A1 (es) Nuevos compuestos de metil-piperidina útiles para inhibir la sintasa-1 de prostaglandina microsomal e2
PE20180232A1 (es) Derivados de indol mono o disustituidos como inhibidores de la replicacion viral del dengue
NI202000058A (es) Moduladores de sting (estimulador de genes de interferón) a base de ciclopentano
SG10201811384TA (en) Mnk inhibitors and methods related thereto
CL2020000610A1 (es) Compuestos de bisamida que activan el sarcómero y sus usos.
CO2017012545A2 (es) Sulfonas tricíclicas como moduladores del receptor huérfano relacionado con retinoide gamma (rorγ)
CO2019009423A2 (es) Inhibidores de mnk sustituidos con piperidina y métodos relacionados con los mismos
CL2021001461A1 (es) Moduladores de trex1
UY38892A (es) Moduladores de sting (estimulador de genes de interferón)
CO2019002523A2 (es) Inhibidores de dopamina–β–hidroxilasa penetrantes de la barrera hematoencefálica
EA202193015A1 (ru) Ингибиторы cdk
NI202100012A (es) Dioxociclobutenilamino-3-hidroxi-picolinamidas n-sustituidas útiles como inhibidores de ccr6
CO2022008719A2 (es) Compuestos para modular la actividad de fxr y usos de los mismos
CR20160527A (es) Derivados de carboxamida
MX2021002503A (es) Métodos de tratamiento de infecciones micobacterianas usando compuestos de tetraciclina.
UY37166A (es) Nucleósidos ánalogos de alquinilo como inhibidores de rinovirus humano